Patents Assigned to Merck
  • Thrombin inhibitors
    Patent number: 6610692
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2 or N; d is CY3 or N; e is CY4 or N; f is CY5 or N; g is CY6 or N; Y4, Y5, and Y6 are independently hydrogen, C1-4 alkyl, or halogen; Y1 and Y2 are independently hydrogen, C1-4 alkyl, C3-7 cycloalkyl, halogen, NH2, OH or C1-4 alkoxy, and Y3 is hydrogen, C1-4 alkyl, C3-7 cycloalkyl, halogen, —CN, NH2, OH or C1-4 alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: August 26, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Philip E. Sanderson, Bruce D. Dorsey, Terry A. Lyle, Matthew G. Stanton, Donnette Staas, Adel M. Naylor-Olsen, Craig Coburn, Matthew M. Morrissette
  • Method for treating or preventing emesis
    Patent number: 6610720
    Abstract: Alpha-2 adrenoreceptor agonists are useful for the treatment and/or prevention of emesis in patients.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: August 26, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventor: Annette Robichaud
  • Thrombin inhibitors
    Patent number: 6610701
    Abstract: Compounds of the invention are useful in inhibiting thrombin and treating blood coagulation and cardiovascular disorders and have the following structure: wherein R3 is hydrogen or halogen, and u is N or CH.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: August 26, 2003
    Assignee: Merck & Co., Inc.
    Inventors: James C. Barrow, Craig Coburn, Harold G. Selnick, Phung L. Ngo
  • Purification process
    Patent number: 6610822
    Abstract: There is disclosed a process for purifying a natural product using a two-phase, multi-solvent system followed by vacuum concentration and back extraction. The method allows for the removal of impurities by controlling the polarity balance of a two-phase system by manipulating the proportions of the four solvents and subsequently the relative distribution of the product versus the impurities.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: August 26, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Martin A. Chandler, Kent E. Goklen, Steven S. Lee, David J. Roush
  • Cyclopeptide derivatives with integrin inhibitor properties
    Patent number: 6610826
    Abstract: Compounds of the formula I R—Q—X  I, in which R, Q, and X are as defined herein, can be used as integrin inhibitors. In particular, compounds of formula I are suitable for the treatment of disorders caused by implants, defects, inflammations and of osteolytic disorders such as osteoporosis, thrombosis, cardiac infarct and arteriosclerosis. These compounds are also suitable for the acceleration and reinforcement of the integration process of implants and biocompatible surfaces into tissue.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: August 26, 2003
    Assignee: Merck Patent Department
    Inventors: Jörg Meyer, Alfred Jonczyk, Berthold Nies, Horst Kessler, Dirk Finsinger, Martin Kantlehner
  • Liquid crystalline medium and liquid crystal display
    Publication number: 20030155552
    Abstract: Liquid crystalline media comprising a dielectrically positive component, component A, containing dielectrically positive compounds, comprising one or more compounds of formula I and one or more compounds of formula II 1
    Type: Application
    Filed: October 23, 2002
    Publication date: August 21, 2003
    Applicant: Merck Patent GmbH
    Inventors: Atsutaka Manabe, Elena Kress, Volker Reiffenrath
  • Triazolo-pyridazine derivatives as ligands for GABA receptors
    Publication number: 20030158203
    Abstract: A class of substituted 1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing a difluoro- or trifluoro-substituted phenyl ring at the 3-position, a triazolyl-methoxy moiety at the 6-position, and a tert-butyl group at the 7-position, are selective ligands for GABAA receptors, in particular having high affinity for &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Application
    Filed: December 20, 2002
    Publication date: August 21, 2003
    Applicant: Merck & Co., Inc.
    Inventors: William Robert Carling, Jose Luis Castro Pineiro, Richard Thomas Lewis, Kevin William Moore, Leslie Joseph Street
  • Use of ectoine or ectoine derivatives in cosmetic formulations
    Publication number: 20030157040
    Abstract: The invention relates to the use of one or more compounds selected from the compounds of formulas (Ia) and (Ib), their physiologically compatible salts and their stereoisomeric forms, where R1, R2, R3, R4 and n have the meanings given in claim no. 1, for the preparation of a cosmetic formulation. Said use is advantageous in protecting and stabilizing the nucleic acids of human skin cells.
    Type: Application
    Filed: January 31, 2003
    Publication date: August 21, 2003
    Applicant: Merck Patent GmbH
    Inventors: Joachim Bunger, Hans-Jurgen Driller
  • Imidazo-triazine derivatives as ligands for GABA receptors
    Patent number: 6608062
    Abstract: A class of substituted 1,2,4-triazolo[4,3-]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position, a substituted alkoxy moiety at the 6-position, and an optionally substituted bicycloalkyl ring system at the 7-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: August 19, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: William Robert Carling, Alexander Richard Guiblin, Kevin William Moore, Christopher Richard Moyes, Michael Rowley, Leslie Joseph Street
  • 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
    Publication number: 20030153600
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: 1
    Type: Application
    Filed: January 14, 2003
    Publication date: August 14, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Process for the synthesis of (R)-1-(3,5-bis(trifluoromethyl)-phenyl)ethan-1-ol by asymmetric transfer hydrogenation
    Publication number: 20030153760
    Abstract: The present invention is concerned with novel processes for the preparation of (R)-1-(3,5-bis(trifluoromethyl)phenyl)ethan-1-ol. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.
    Type: Application
    Filed: December 20, 2002
    Publication date: August 14, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Paul Devine, Hansen Karl
  • Solutions and processes for removal of sidewall residue after dry etching
    Patent number: 6605230
    Abstract: The present invention relates to a novel process for removing sidewall residue after dry-etching process. Conventionally, after dry-etching, photoresist and sidewall residues are removed by ozone ashing and hot sulfuric acid. Normally, they are hard to be removed completely. It was found in the present invention that the addition of fluorine-containing compound, preferably hydrogen fluoride and ammonium fluoride, in sulfuric acid results in complete removal of photoresist and sidewall residue without the need for stripper. The process is simple and does not affect the original procedures or the other films on the substrate. The present invention also relates to a novel solution for removing sidewall residue after dry-etching, which comprises sulfuric acid and a fluorine-containing compound, preferably hydrogen fluoride and ammonium fluoride, in the range of from 10:1 to 1000:1 by weight.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: August 12, 2003
    Assignee: Merck Patent GmbH
    Inventors: Ming-Chi Liaw, Tien-Sheng Chao, Tan-Fu Lei
  • Process for making spirolactone compounds
    Patent number: 6605720
    Abstract: This invention relates to processes for making spirolactone compounds analogous to formula I:
    Type: Grant
    Filed: January 23, 2003
    Date of Patent: August 12, 2003
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Kenji Maeda, Shinji Kato, Takehiko Iida, David M. Tschaen
  • Protein tyrosine phosphate-1B (PTP-1B) deficient mice and uses thereof
    Patent number: 6605753
    Abstract: The present invention provides mice that have had their PTP-1B genes disrupted by targeted homologous recombination. The mice have no detectable PTP-1B protein, yet appear to be physiologically normal. However, in the fed state on a normal diet, the mice have half the level of circulating insulin as their wild-type littermates. In glucose and insulin tolerance tests, the mice show an increased insulin sensitivity. When fed a high fat, high carbohydrate diet, the mice show a resistance to weight gain as compared to their wild-type littermates. Methods making the mice and cell lines derived from the mice are also provided. The present invention also provides methods of identifying inhibitors of the enzymatic activity of PTP-1B as well as inhibitors identified by such methods.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: August 12, 2003
    Assignees: Merck & Co., Inc., McGill University
    Inventors: Brian Kennedy, Paul Payette, Michael Gresser, Chidambaram Ramachandran, Michel Tremblay, Mounib Elchebly
  • STN liquid crystal display
    Publication number: 20030148043
    Abstract: The invention relates to supertwist liquid-crystal displays (SLCDs) having very short response times and good steepnesses and angular dependences and to the novel nematic liquid-crystal mixtures employed therein, which are distinguished by the fact that they comprise at least one compound of the formula IA 1
    Type: Application
    Filed: December 23, 2002
    Publication date: August 7, 2003
    Applicant: Merck Patent GmbH
    Inventor: Harald Hirschmann
  • Cosmetic body pigment and process for preparing the same
    Publication number: 20030147819
    Abstract: A cosmetic body pigment having a good skin feel, no blue color, a high soft focusing effect (low viewing angle dependency of reflected light intensity), a natural color tone against the skin, and a moderate hiding power (wrinkle hiding effect) is provided. The cosmetic body pigment is characterized in that TiO2 fine particles are deposited separately with form of mono layer on the surface of a thin-platelet like substrate.
    Type: Application
    Filed: January 22, 2003
    Publication date: August 7, 2003
    Applicant: Merck Patent GmbH
    Inventor: Yukitaka Watanabe
  • Pearlescent pigments
    Publication number: 20030147820
    Abstract: The present invention relates to pearlescent pigments based on substrates coated with one or more layers of nitrides or oxynitrides to a method for the production of such pigments and their use in plastics, paints, coatings, powder coatings, inks, printing inks, glasses, ceramic products, agriculture foils, for lasermarking of papers and plastics, security applications and in cosmetic formulations.
    Type: Application
    Filed: January 31, 2003
    Publication date: August 7, 2003
    Applicant: MERCK PAPTENTGESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Stephane Bertaux, Peter Reynders, Jens-Uwe Wichmann, Eberhard Schweda
  • Use of ectoine or ectoine derivatives in cosmetic formulations
    Patent number: 6602514
    Abstract: The use of one or more compounds chosen from the compounds of the formulae Ia and Ib the physiologically compatible salts of the compounds of the formulae Ia and Ib and the stereoisomeric forms of the compounds of the formulae Ia and Ib, where R1, R2, R3, R4 and n have the meanings given in claim 1, for the preparation of a cosmetic formulation is advantageously suitable, e.g., for protecting cells, proteins and/or biomembranes of the human skin, for protecting the microflora of the human skin, and/or for stabilizing the skin barrier.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Joachim Bünger, Hans-Jürgen Driller, Roland Martin
  • Electro-optical liquid-crystal display
    Patent number: 6602562
    Abstract: The invention generally relates to an electro-optical liquid-crystal display having a re-alignment layer, for re-aligning the liquid crystals, whose field has a component parallel to the liquid-crystal layer which is desirable for the re-alignment, including a liquid-crystalline medium of positive dielectric anisotropy, where the medium can include one or more compounds of the formula I and one or more compounds selected from the group of compounds of the formulae II and III in which R1, R2 and R3 are each, independent of one another, alkyl or alkoxy having 1 to 7 carbon atoms or alkenyl, alkenyloxy or alkoxyalkyl having 2 to 7 carbon atoms, Y11, Y12, Y21, Y22, Y31 and Y32 are each, independent of one another, H or F, are each, independent of one another,  and Q—X is F, Cl, —OCF2H or —OCF3.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: August 5, 2003
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Shinji Nakajima, Hideo Ichinose, Akiko Takashima, Yasushi Sugiyama
  • Process for purifying human papillomavirus virus-like particles
    Patent number: 6602697
    Abstract: A process for purifying papillomavirus virus-like particles (VLPs) includes the step of passing a partially purified VLP-containing solution through a hydroxyapatite chromatography column. The VLPs are then eluted using a buffer containing phosphate anion. The advantages of this method include the recovery of a high yield of intact VLPs.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: August 5, 2003
    Assignee: Merck & Co., Inc.
    Inventor: James C. Cook, III